|Table of Contents|

Clinical study of safety and efficacy of the neoadjuvant chemotherapy of XELOX and FOLFOX4 in locally advanced gastric cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 04
Page:
538-542
Research Field:
Publishing date:

Info

Title:
Clinical study of safety and efficacy of the neoadjuvant chemotherapy of XELOX and FOLFOX4 in locally advanced gastric cancer
Author(s):
Su Liping1; Chen Jing2; Zhu Bo1; Wang Yongxi1; Ma Jinping1; Che Jun1; Zhang Michun1
1.Department of Gastroenterology,Xianyang Central Hospital,Shaanxi Xianyang 712000,China;2.The First People's Hospital of Xianyang City,Shaanxi Xianyang 712000,China.
Keywords:
advanced gastric cancer; XELOX; FOLFOX4; clinical outcomes; adverse reactions
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2018.04.014
Abstract:
Objective:To explore safety and efficacy of the neoadjuvant chemotherapy of XELOX and FOLFOX4 in locally advanced gastric cancer.Methods:100 patients with locally advanced gastric cancer treated in our hospital from January 2014 to January 2015 were randomly divided into two groups:The observation group（n=50) and the control group（n=50),and the observation group patients received the chemotherapy of XELOX while the control group patients received the chemotherapy of FOLFOX4.The major clinical outcomes and adverse reactions of the two groups patients were observed.Results:The mortality and the recurrence rates of the two group had no statistically significant differences［(32.00% vs 42.00%,P=0.300) and （70.00% vs 84.00%,P=0.096)］.The progression-free survival of the patients in the observation group was significantly longer than that in the control group（P=0.022).The health-related quality of life（SF-36) of the patients in two groups on admission had no statistically significant differences（81.56±6.66 vs 81.58±7.03,P=0.988).Compared with the control group,the health-related quality of life（SF-36) of the observation group at 1 month and 3 months since the admission both increased significantly ［(75.34±6.67 vs 71.66±7.35,P=0.010) and （68.24±6.44 vs 62.68±9.12,P=0.001)］.The occurrence rates of nausea,vomiting,neurotoxicity and other adverse reactions in the observation group were significantly lower than the control group,but the incidence of the hand foot syndrome in the observation group was significantly higher than the control group,and the differences were statistically significant（P＜0.05).Conclusion:XELOX could prolong the progression-free survival of the patients with locally advanced gastric cancer and decrease the incidence of adverse reactions,but increase the incidence of hand foot syndrome.

References:

[1] Liu KT,Wan JF,Yu GH,et al.The recommended treatment strategy for locally advanced gastric cancer in elderly patients aged 75 years and older:A surveillance,epidemiology,and end results database analysis［J］.J Cancer Res Clin Oncol,2017,143(2):313-320.
[2] Zhang G,Zhao X,Li J,et al.Racial disparities in stage-specific gastric cancer:Analysis of results from the surveillance epidemiology and end results（SEER) program database［J］.J Investig Med,2017,12(4):771-777.
[3] Li W,Song D,Li H,et al.Reduction in peripheral CD19+CD24hCD27+ B cell frequency predicts favourable clinical course in XELOX-treated patients with advanced gastric cancer［J］.Cell Physiol Biochem,2017,41(5):2045-2052.
[4] Lim KH,Lee HY,Park SB,et al.Feasibility of modified FOLFOX in elderly patients aged ≥80 years with metastatic gastric cancer or colorectal cancer［J］.Oncology,2017,8(4):762-771.
[5] Suh BJ.A case of advanced gastric cancer with para-aortic lymph node metastasis treated with preoperative FOLFOX chemotherapy followed by radical subtotal gastrectomy and D2 lymph node dissection［J］.Case Rep Oncol,2017,10(1):182-191.
[6] Zhang RX,Yan H,Wang M,et al.A Meta-analysis on the effects of regimen XELOX versus FOLFOXs for treatment of Chinese patients with metastatic gastric cancer［J］.J Capital Medical University,2013,34(03):422-427.［张瑞雪,闫涵,王民,等.XELOX方案与FOLFOXs方案治疗中国晚期胃癌患者的Meta分析［J］.首都医科大学学报,2013,34(03):422-427.］
[7] Wu MQ,Zhou XK,Li P,et al.Efficacy of FOLFOX and XELOX chemotherapy combined with laparoscopy for treatment of advanced gastric cancer［J］.Chin J Gastroenterol,2014,19(01):36-39.［吴梅青,周旭坤,李平,等.FOLFOX、XELOX方案联合腹腔镜治疗进展期胃癌的研究［J］.胃肠病学,2014,19(01):36-39.］
[8] Aoyama T,Nishikawa K,Fujitani K,et al.Early results of a randomized two-by-two factorial phase Ⅱ trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer［J］.Ann Oncol,2017,32(12):6638-6644.
[9] Kochi M,Fujii M,Kanamori N,et al.Phase Ⅱ study of neoadjuvant chemotherapy with S-1 and CDDP in patients with lymph node metastatic stage Ⅱ or Ⅲ gastric cancer［J］.Am J Clin Oncol,2017,40(1):17-21.
[10] Palmela C,Velho S,Agostinho L,et al.Body composition as a prognostic factor of neoadjuvant chemotherapy toxicity and outcome in patients with locally advanced gastric cancer［J］.J Gastric Cancer,2017,17(1):74-87.
[11] Liu J,Liu T.Curative effect and safety assessment of XELOX and FOLFOX4 chemotherapy regimens for patients with advanced gastric cancer［J］.Journal of Tianjin Medical University,2015,12(02):140-142.［刘嘉,刘彤.应用XELOX及FOLFOX4方案治疗进展期胃癌疗效及安全性评价［J］.天津医科大学学报,2015,12(02):140-142.］
[12] Wang HZ,Wang XH,Lv ZC.A randomized clinical study of XELOX compared with FOLFOX4 in the treatment of advanced gastric cancer［J］.Modern Oncology,2010,18(05):947-950.［王海忠,王湘辉,吕志诚.XELOX与FOLFOX4方案治疗进展期胃癌的随机对照临床研究［J］.现代肿瘤医学,2010,18(05):947-950.］
[13] Fan ZM,He HG,Huang CH,et al.Clinical effects of FOLFOX4 and XELOX on patients with advanced gastric cancer［J］.The Practical J Cancer,2013,28(04):396-398.［樊志明,贺鸿桂,黄超红,等.FOLFOX4和XELOX治疗进展期胃癌的临床疗效比较［J］.实用癌症杂志,2013,28(04):396-398.］
[14] Zhou W,Chen QQ,Luo HM.Efficacy and safety of XELOX and FOLFOX4 regimens in the treatment of patients with advanced gastric carcinoma［J］.Journal of Clinical Medicine in Practice,2016,43(09):64-66.［周娓,陈泉全,罗红梅.XELOX与FOLFOX4方案治疗进展期胃癌疗效及安全性［J］.实用临床医药杂志,2016,43(09):64-66.］
[15] Schmoll HJ,Cartwright T,Tabernero J,et al.Phase Ⅲ trial of capecitabine plus oxaliplatin as adjuvant therapy for stage Ⅲ colon cancer:A planned safety analysis in 1,864 patients［J］.J Clin Oncol,2007,25(1):102-109.

Memo

Memo:
陕西省卫生厅科学研究项目(编号：2010H22)
Last Update: 2017-12-29